Antiemetic research: A look to the future

Jørn Herrstedt*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    The classification of receptor involved in the emetic reflex has completely changed during the past 10 years. Today investigation agents acting as combined 5-HT3 antagonists/5-HT4 agonists, dopamine D2/D3 antagonists and the neurokinin1 antagonists are in focus. Positron emission tomography (PET) is rapidly advancing as an investigational tool in the detection and staging of cancer and in the evaluation of response to treatment. It is emphasized that PET could also be useful in further investigations of the pathophysiology of emesis. Through antiemetic treatment has been optimized, delayed emesis, emesis during multiple cycles and, especially, refractory emesis after chemotherapy continue to present significant challenges requiring further clinical investigation, as does the syndrome of chronic nausea and vomiting in patients with advanced cancer.

    Sider (fra-til)8-12
    Antal sider5
    TidsskriftSupportive Care in Cancer
    Udgave nummer1
    StatusUdgivet - dec. 1997


    Udforsk hvilke forskningsemner 'Antiemetic research: A look to the future' indeholder.